A Phase 2, Double-Blind, Randomized, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety-Tolerability of a Single Oral Dose of EP102 Self-Administered at Home by Adult Participants Experiencing Moderate-To-Severe Migraine Headache

Participants with receive a bottle of investigational product (IP) containing two oral capsules. The bottle of the investigational product will contain either: • EP102: 2 capsules, each containing 200 mg of EP102 (total of 400 mg of EP102-04) • EP102: 1 capsule containing 200 mg of EP102 and 1 capsule containing placebo (total of 200 mg of EP102-04) • Placebo: 2 capsules, each containing placebo ( no active medication) Participants will visit the clinical trial centre three (3) times in total: • Visit 1 - a screening visit to see if you are eligible for the trial • Visit 2 - for a final eligibility check and for administration of a test-dose of the investigational product • Visit 3 - 3-10 days after the participant has self-administered the investigational product at home Single oral dose of EP102 200, EP102 400 mg, or placebo will be administered as a test dose in the clinic while the participant is not experiencing a migraine attack. This is being conducted to assess the safety and tolerability of a single oral dose of EP102 200 mg or EP102 400 mg. This will be evaluated by the collecting of adverse events, changes in vital signs, oxygen saturation, and results of orthostatic testing. If orthostatic hypotension is diagnosed after randomization at Visit 2 at the test dose the participant is to be withdrawn from the study. Randomized participants will have up to 45 days after the randomization visit (Visit 2) to treat a qualifying migraine headache of at least moderate pain severity with the assigned blinded IP. Participants will be instructed to store the bottles in a cool dry place outside of direct sunlight. Participants are to bring their IP bottles with them to the end-of-study visit for IP accountability. Participants must agree to adhere to clinic visits and all other requirements of the study.

Participants with receive a bottle of investigational product (IP) to take home. Each bottle will contain three oral capsules. The bottle of the investigational product will contain either: • EP102: 3 capsules, each containing 200 mg of EP102 (total of 600 mg) or • Placebo: 3 capsules, each containing placebo (no active medication) Participants will visit the clinical trial centre three (3) times in total: • Visit 1 - a screening visit to see if you are eligible for the trial • Visit 2 - for a final eligibility check and for administration of a test-dose of the investigational product • Visit 3 - 3-10 days after the participant has self-administered the investigational product at home A single oral dose of EP102 600 mg or placebo will be administered as a test dose in the clinic while the participant is not experiencing a migraine attack. This is being conducted to assess the safety and tolerability of a single oral dose of EP102 600 mg. This will be evaluated by the collecting of adverse events, changes in vital signs, oxygen saturation, and results of orthostatic testing. If orthostatic hypotension is diagnosed after randomization at Visit 2 at the test dose the participant is to be withdrawn from the study. Randomized participants will have up to 45 days after the randomization visit (Visit 2) to treat a qualifying migraine headache of at least moderate pain severity with the assigned blinded IP. Participants will be instructed to store the bottles in a cool dry place outside of direct sunlight. Participants are to bring their IP bottles with them to the end-of-study visit for IP accountability. Participants must agree to adhere to clinic visits and all other requirements of the study.